10-Q: Palisade Bio Reports Q3 2024 Results, Advances PALI-2108 Clinical Program

Palisade Bio's Q3 2024 report highlights progress in their PALI-2108 clinical program, including the commencement of a Phase 1 trial, while also noting ongoing financial challenges.

Summary

• Palisade Bio reported a net loss of $3.487 million for the three months ended September 30, 2024, and a net loss of $11.094 million for the nine months ended September 30, 2024.
• The company's cash and cash equivalents stood at $8.040 million as of September 30, 2024.
• Research and development expenses were $2.137 million for the quarter and $6.979 million for the nine-month period.
• General and administrative expenses were $1.456 million for the quarter and $4.498 million for the nine-month period.
• The company commenced a Phase 1 clinical trial of PALI-2108 in Canada after receiving a No Objection Letter from Health Canada.
• Palisade Bio anticipates filing an Investigational New Drug Application with the FDA in 2025.
• The company completed a private placement in May 2024, raising net proceeds of approximately $3.5 million.
• A warrant inducement transaction in February 2024 generated net proceeds of approximately $2.2 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in the clinical program, the financial situation is concerning with substantial doubt about the company's ability to continue as a going concern. The material weakness in internal controls is also a negative factor.

Positives

• The company successfully commenced a Phase 1 clinical trial for PALI-2108 in Canada.
• The company is progressing towards filing an IND with the FDA to begin clinical trials in the United States.
• Recent financings have provided additional capital to support operations.
• The company recognized a non-cash gain due to a decrease in the fair value of the Giiant Milestone Payments.

Negatives

• The company reported a net loss of $3.487 million for the quarter and $11.094 million for the nine-month period.
• The company has a limited operating history and has never generated revenue from product sales.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a history of net operating losses and expects to continue to incur losses.
• The company identified a material weakness in its internal control over financial reporting.

Risks

• The company's business depends on the successful clinical development, regulatory approval, and commercialization of PALI-2108.
• There are substantial risks inherent in drug development, and the company may not be able to successfully develop PALI-2108.
• The company depends on a license agreement with Giiant, and termination of this agreement could harm the business.
• The company may find it difficult to enroll patients in clinical trials, which could delay or prevent progress.
• The company expects that operations and development of PALI-2108 will require substantially more capital than currently available.
• The company's product candidates may cause undesirable side effects or have other unexpected properties.
• There is no assurance that the company's product candidates will obtain regulatory approval.
• The company is conducting a Phase 1 clinical trial in Canada, and the FDA may not accept data from such trials.
• The company has a limited operating history and has never generated any revenue from product sales.
• The company's common stock could be delisted from the Nasdaq Stock Market if it fails to maintain compliance with listing standards.
• The company's success depends on attracting and retaining senior management and scientists.
• The company may choose to discontinue developing or commercializing any of its product candidates.
• The company's inability to successfully in-license, acquire, develop and market additional product candidates could impair its ability to grow.
• The company anticipates relying on third-party CROs and other third parties to conduct and oversee clinical trials.
• The company expects to rely on collaborations with third parties for the successful development and commercialization of product candidates.
• The company anticipates relying completely on third-party contractors to supply, manufacture and distribute clinical drug supplies.
• The company has expressed substantial doubt about its ability to continue as a going concern.
• The company has a history of net operating losses and expects to continue to incur losses.
• Failure to remediate a material weakness in internal controls over financial reporting could result in material misstatements.
• The company may not be able to obtain, maintain or enforce global patent rights or other intellectual property rights.
• If the company fails to comply with obligations under intellectual property license agreements, it could lose important license rights.
• The company will need to raise additional capital in the future, which may not be available on favorable terms or at all.
• The company's common stock price may be highly volatile.
• If the company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements could be impaired.
• The company's Board of Directors has broad discretion to issue additional securities, which might dilute the net tangible book value per share.

Future Outlook

The company plans to continue to fund its operations through its cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third-party funding, and potential licensing or collaboration arrangements. The company anticipates filing an Investigational New Drug Application with the FDA in 2025 and commencing clinical trials of PALI-2108 in the United States during the second half of 2025. Topline data from the Phase 1 clinical study is expected during the second quarter of 2025.

Management Comments

• Management believes that the company has sufficient cash to fund its currently planned operations through the first quarter of 2025.
• Management has evaluated all conditions and events that raise substantial doubt about the company's ability to continue as a going concern within one year after the date that these financial statements are issued.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. The company's lead product candidate, PALI-2108, is being developed as a treatment for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company's approach involves a biomarker-based patient selection strategy, which is a growing trend in the industry.

Comparison to Industry Standards

• The company's cash burn rate is typical for a clinical-stage biopharmaceutical company, but the company's cash runway is limited to the first quarter of 2025, which is shorter than many comparable companies.
• The company's research and development expenses are in line with other companies at a similar stage of development, but the company's general and administrative expenses are relatively high.
• The company's reliance on third-party CROs and manufacturers is standard practice in the industry.
• The company's focus on a biomarker-based patient selection approach is a positive differentiator, but the company's success will depend on the validation of these biomarkers.
• The company's recent financings are necessary to continue operations, but the company will likely need to raise additional capital in the future.
• The company's ongoing material weakness in internal controls is a concern and needs to be addressed.

Management Changes

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional capital.
• Employees may be affected by potential cost-reduction measures or changes in the company's operations.
• Customers (potential patients) may benefit from the development of new treatments, but there is no guarantee of success.
• Suppliers and creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company will continue to enroll subjects in the Phase 1 clinical trial of PALI-2108 in Canada.
• The company plans to file an Investigational New Drug Application with the FDA in 2025.
• The company anticipates commencing clinical trials of PALI-2108 in the United States during the second half of 2025.
• The company will continue to work on remediating the material weakness in internal control over financial reporting.

Key Dates

Keywords

PALI-2108, Inflammatory Bowel Disease, Ulcerative Colitis, Clinical Trial, Biopharmaceutical, Phase 1, FDA, Giiant Pharma, Warrant Inducement, Equity Offering